Skip to main content
Clinical Trials/JPRN-jRCTs042180119
JPRN-jRCTs042180119
Completed
Phase 2

A feasibility study of intensity modulated radiotherapy with chemotherapy for locally advanced non-small-cell lung cancer

Harada Hideyuki0 sites22 target enrollmentMarch 19, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Clinical stage 3 non-small-cell lung cancer
Sponsor
Harada Hideyuki
Enrollment
22
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The primary endpoint for tolerability of chemoradiotherapy with intensity-modulated radiotherapy could not be achieved. However, intensity-modulated radiotherapy could be completed in all but one case, demonstrating good survival and safety.

Registry
who.int
Start Date
March 19, 2019
End Date
May 11, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Harada Hideyuki

Eligibility Criteria

Inclusion Criteria

  • 1\)Non\-small cell lung cancer(NSCLC) diagnosed by cytological or histological examination
  • 2\)Inoperable
  • 3\)Clinical stage 3 NSCLC, possible for definitive radiotherapy
  • 4\)No previous chemotherapy or radiotherapy
  • 5\)Measurable lesions
  • 6\)Age; 20 \-75 years old
  • 7\)ECOG performance status:0\-1
  • 8\)Ingestible
  • 9\)Sufficient function in bone marrow, heart, lung, liver and kidney
  • 10\)Written informed consent

Exclusion Criteria

  • 1\)Active double cancer
  • 2\)Severe infection or morbidity
  • 3\)HBs antigen positive
  • 4\)Previous thoracic radiotherapy
  • 5\)Interstitial pneumonia or fibrosis on CT
  • 6\)Severe emphysema or chronic bronchitis or asthma
  • 7\)Severe drug allergy
  • 8\)Severe diabetes
  • 9\)Unstable angina or myocardial infarction within 6 months
  • 10\)Febrile more than or equal to 38 degree

Outcomes

Primary Outcomes

Not specified

Similar Trials